Russell Investments Group
GTBP icon

Russell Investments Group’s GT Biopharma GTBP Stock Holding History

Russell Investments Group’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-241
Closed -$21K – 2934
2022
Q2 		$21K Sell
241
-126
-34% -$9.55K ﹤0.01% 2794
2022
Q1 		$31K Buy
+367
New +$32.4K ﹤0.01% 2656
2021
Q4 		– Sell
-321
Closed -$64K – 3044
2021
Q3 		$64K Buy
+321
New +$96.6K ﹤0.01% 2925

Other funds holding GTBP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CLOS
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $8.13B AUM 26.03% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Russell Investments Group's GTBP Position: Q3 2022 in Review

Russell Investments Group sold out of GT Biopharma (GTBP) in Q3 2022, closing a stake of 241 shares — an estimated $21K sold.

Russell Investments Group first reported a position in GTBP in Q3 2021 and held it in 3 quarters. The position peaked at $64K in Q3 2021. 34 funds tracked by Wall St. Rank hold GTBP as of Q3 2022.

  • Russell Investments Group reported no remaining GT Biopharma position as of Q3 2022 after selling out during the quarter.
  • Russell Investments Group sold 241 GT Biopharma shares in Q3 2022, an estimated $21K.
  • Russell Investments Group first reported a position in GT Biopharma in Q3 2021 and held it in 3 quarters.
  • Russell Investments Group's GT Biopharma position peaked at $64K in Q3 2021.
  • 34 funds tracked by Wall St. Rank held GT Biopharma as of Q3 2022.

Based on Russell Investments Group's 13F filing for Q3 2022, filed 4 Nov 2022.